Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LAMA/LABA

- PMLiVE

AstraZeneca chooses Ireland for $360m manufacturing site

The next-generation facility will make small molecule active ingredients, future-proofing the company’s supply chain and boosting the Irish life sciences sector

- PMLiVE

AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients

The drug tripled patient survival after three years in the longest-ever follow-up in extensive-stage small cell lung cancer

- PMLiVE

New data advances AstraZeneca’s “revolution in oncology”

In a busy few weeks for AstraZeneca, the company will present data on 14 approved and potential drugs in lung and breast cancer

- PMLiVE

AZ’s new rare disease unit wins in Wilson disease

Alexion purchase looks increasingly ‘copper-bottomed’ as AstraZeneca prepares to submit data for ALXN1840 in Wilson disease

AstraZeneca AZ

AstraZeneca’s Forxiga approved in Japan for the treatment of CKD

Approval was based on positive data from the phase 3 trial for chronic kidney disease

- PMLiVE

AZ to seek approval for “long-acting” COVID-19 antibodies

AZD7442 significantly reduced the risk of developing symptomatic COVID-19 in phase 3 trial and is a one-dose treatment that can be given via an intramuscular injection

- PMLiVE

COVID-19 vaccine protection wanes over time, backing up the need for boosters

While both Pfizer/BioNTech and AstraZeneca’s vaccines offer good protection, a new UK study shows the protection reduces over time and the UK's booster campaign is likely to begin in September

- PMLiVE

Price hike for Pfizer/BioNTech COVID-19 vaccine as UK orders boosters for 2022

The UK will pay £22 a shot, up from £18 previously, as confirmation of the UK's COVID-19 booster campaign for this winter is awaited, while the EU and the US...

- PMLiVE

Valneva’s COVID-19 vaccine to be tested in older people

The trial for VLA2001 will involve people over the age of 56 in New Zealand and aims to generate additional safety and immunogenicity data in older people

- PMLiVE

South Korean company SK bioscience moves into phase 3 trials for its COVID-19 vaccine

Part of the Wave 2 vaccine programme, GBP510 will bolster South Korea’s domestic supply if successful

- PMLiVE

FDA requests further safety trials for AZ, FibroGen’s roxadustat

The response follows concerns over serious thrombotic events and seizures

- PMLiVE

AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria

Real-world data shows similar safety profile for Vaxzevria and mRNA-based jabs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links